Biofrontera Inc. sold its product Xepi® to Pelthos Therapeutics for up to $10 million, structured with $3 million paid upfront and potential earnouts based on future sales. The agreement was finalized on November 6, 2025, and includes consulting arrangements involving the CEO's spouse.